Amarin Corp Plcuk (AMRN) Net Cash Flow (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Net Cash Flow of -$3.6 million for Q1 2026, down 137.58% YoY from $9.6 million in Q1 2025, and down 130.59% sequentially from $11.8 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Net Cash Flow (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Net Cash Flow across 17 years of filings, most recently posting -$3.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 137.58% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at $11.4 million (up 112.09% YoY), while the FY2025 annual figure was $13.5 million, up 117.24% from the prior year.
- Net Cash Flow fell to -$3.6 million in Q1 2026, from $11.8 million in the prior quarter.
- Over the last five years, Net Cash Flow for AMRN reached as high as $41.6 million in Q2 2023 and fell as low as -$71.6 million in Q4 2023.
- The 5-year median for Net Cash Flow is -$303000.0 (2022), against an average of -$5.4 million.
- Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 8564.69% — and 2025, when it soared 1331.97%.
- A 5-year view of Net Cash Flow shows it stood at -$26.2 million in 2022, then tumbled by 172.83% to -$71.6 million in 2023, then surged by 49.51% to -$36.1 million in 2024, then surged by 132.54% to $11.8 million in 2025, then plunged by 130.59% to -$3.6 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$3.6 million, $11.8 million, and -$25.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -2.05 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.00 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.17 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -1.53 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.60 Mn |
| Mar 31, 2026 | -3.60 Mn |
| Dec 31, 2025 | 11.76 Mn |
| Dec 31, 2025 | 11.76 Mn |
| Sep 30, 2025 | -25.07 Mn |
| Sep 30, 2025 | -25.07 Mn |
| Jun 30, 2025 | 28.35 Mn |
| Jun 30, 2025 | 28.35 Mn |
| Mar 31, 2025 | -1.51 Mn |
| Mar 31, 2025 | -1.51 Mn |
| Dec 31, 2024 | -36.13 Mn |
| Dec 31, 2024 | -36.13 Mn |
| Sep 30, 2024 | -58.98 Mn |
| Sep 30, 2024 | -58.98 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 14.69 Mn |
| Mar 31, 2024 | 14.69 Mn |
| Dec 31, 2023 | -71.56 Mn |
| Dec 31, 2023 | -71.56 Mn |